Fluticasone Furoate vs fluticasone furoate/vilanterol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Glucocorticoid receptor · full Asthma pipeline

Fluticasone Furoate · Arnuity Ellipta

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule (corticosteroid)
Partial signal

NCT00603382 · Phase 2 · completed

This was a randomized, double-blind, placebo-controlled trial with about 95 to 110 people per group. Its primary lung-function comparison (trough FEV1) was significant for the 50, 100 and 200 microgram doses but not for the lowest 25 microgram dose, so the primary result is mixed across the doses tested.

Reported efficacy

Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409) (met)

Result source: NCT00603278

fluticasone furoate/vilanterol · Breo Ellipta

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule combination
Reliable signal

NCT01086384 · Phase 3 · completed

This was a randomized, triple-blind, active-controlled trial with approximately 2,019 treated participants. Its primary hard clinical endpoint—having one or more severe asthma exacerbations—favored fluticasone furoate/vilanterol and was statistically significant.

Reported efficacy

Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010 (met)

Result source: NCT01086384

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFluticasone Furoatefluticasone furoate/​vilanterol
Severe exacerbations, annualised rate—Trial running · NCT04651777—Trial running · NCT05757102
Trough FEV1, change0.2 vs 0.0+0.1 vs placebo100 µg OD · wk 24 · n 111NCT01159912
19 other results
  • 0.4 vs 0.2 100/25 µg OD · wk 12 · n 200 · Phase 3 · primary NCT01165138
  • 0.2 vs 0.0 50 µg OD · wk 12 · n 108 · Phase 3 · primary NCT01436071
  • 0.4 vs 0.2 200/25 µg OD · wk 24 · n 187 · Phase 3 · primary NCT01134042
  • 0.5 vs 0.4 200/25 µg OD · wk 12 · n 337 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 100/25 µg · wk 36 · n 926 · Phase 3 · secondary NCT01086384
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.4 vs 0.4 100/25 µg OD · wk 12 · n 334 · Phase 3 · secondary NCT01686633
  • 0.2 vs -0.1 200 µg OD · wk 8 · n 101 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 200 µg OD · wk 8 · n 99 · Phase 2 · primary NCT00603746
  • 0.1 vs -0.1 100 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 800 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.0 600 µg OD · wk 8 · n 107 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.1 400 µg OD · wk 8 · n 97 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 400 µg OD · wk 8 · n 101 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.1 300 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603278
  • 0.2 vs 0.1 100 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • -0.5 vs -0.8 100/25 µg OD · wk 4.14 · n 46 · Phase 2 · secondary NCT01128569
  • 0.1 vs 0.1 50 µg OD · wk 12 · n 112 · Phase 2 · secondary NCT01563029
  • 0.3 vs 0.1 25 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
0.4 vs 0.2+0.2 vs placebo100/25 µg OD · wk 12 · n 200NCT01165138
8 other results
  • 0.4 vs 0.2 200/25 µg OD · wk 24 · n 187 · Phase 3 · primary NCT01134042
  • 0.5 vs 0.4 200/25 µg OD · wk 12 · n 337 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 100/25 µg · wk 36 · n 926 · Phase 3 · secondary NCT01086384
  • 0.3 vs 0.3 100/25 µg OD · wk 24 · n 397 · Phase 3 · secondary NCT01147848
  • 0.4 vs 0.4 100/25 µg OD · wk 12 · n 334 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 wk 12 · n 417 · Phase 3 · secondary NCT03248128
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.3 vs 0.2 wk 12 · n 307 · Phase 3 · secondary NCT03248128
ACQ-5, change—Trial running · NCT04651777-1.2 vs -1.1vs FFwk 24 · n 385NCT03248128
1 other result
  • -1.3 vs -1.1 wk 24 · n 291 · Phase 3 · secondary NCT03248128
OCS dose reduction—Trial running · NCT04651777—Trial running · NCT05757102

Severe exacerbations, annualised rate

Fluticasone Furoate
—Trial running · NCT04651777
fluticasone furoate/​vilanterol
—Trial running · NCT05757102

Trough FEV1, change

Fluticasone Furoate
0.2 vs 0.0+0.1 vs placebo100 µg OD · wk 24 · n 111NCT01159912
19 other results
  • 0.4 vs 0.2 100/25 µg OD · wk 12 · n 200 · Phase 3 · primary NCT01165138
  • 0.2 vs 0.0 50 µg OD · wk 12 · n 108 · Phase 3 · primary NCT01436071
  • 0.4 vs 0.2 200/25 µg OD · wk 24 · n 187 · Phase 3 · primary NCT01134042
  • 0.5 vs 0.4 200/25 µg OD · wk 12 · n 337 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 100/25 µg · wk 36 · n 926 · Phase 3 · secondary NCT01086384
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.4 vs 0.4 100/25 µg OD · wk 12 · n 334 · Phase 3 · secondary NCT01686633
  • 0.2 vs -0.1 200 µg OD · wk 8 · n 101 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 200 µg OD · wk 8 · n 99 · Phase 2 · primary NCT00603746
  • 0.1 vs -0.1 100 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 800 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.0 600 µg OD · wk 8 · n 107 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.1 400 µg OD · wk 8 · n 97 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 400 µg OD · wk 8 · n 101 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.1 300 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603278
  • 0.2 vs 0.1 100 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • -0.5 vs -0.8 100/25 µg OD · wk 4.14 · n 46 · Phase 2 · secondary NCT01128569
  • 0.1 vs 0.1 50 µg OD · wk 12 · n 112 · Phase 2 · secondary NCT01563029
  • 0.3 vs 0.1 25 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
fluticasone furoate/​vilanterol
0.4 vs 0.2+0.2 vs placebo100/25 µg OD · wk 12 · n 200NCT01165138
8 other results
  • 0.4 vs 0.2 200/25 µg OD · wk 24 · n 187 · Phase 3 · primary NCT01134042
  • 0.5 vs 0.4 200/25 µg OD · wk 12 · n 337 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 100/25 µg · wk 36 · n 926 · Phase 3 · secondary NCT01086384
  • 0.3 vs 0.3 100/25 µg OD · wk 24 · n 397 · Phase 3 · secondary NCT01147848
  • 0.4 vs 0.4 100/25 µg OD · wk 12 · n 334 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 wk 12 · n 417 · Phase 3 · secondary NCT03248128
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.3 vs 0.2 wk 12 · n 307 · Phase 3 · secondary NCT03248128

ACQ-5, change

Fluticasone Furoate
—Trial running · NCT04651777
fluticasone furoate/​vilanterol
-1.2 vs -1.1vs FFwk 24 · n 385NCT03248128
1 other result
  • -1.3 vs -1.1 wk 24 · n 291 · Phase 3 · secondary NCT03248128

OCS dose reduction

Fluticasone Furoate
—Trial running · NCT04651777
fluticasone furoate/​vilanterol
—Trial running · NCT05757102
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
19 other shared endpoints and safety

Coverage. Fluticasone Furoate: 23 of 23 rows · fluticasone furoate/vilanterol: 23 of 23 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFluticasone Furoate
Rows use multiple source trials
fluticasone furoate/​vilanterol
Rows use multiple source trials
ACT Control
responder rate · % of participants
99.1% (n=112) vs 97.4% (n=114) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
99.1% (n=112) vs 97.4% (n=114) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
ACT Total
absolute change · score
-0.3 vs -0.6 FP 100 mcg BD score @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.6 FP 100 mcg BD score @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
AQLQ Total
absolute change · score
0.84 vs 0.51 placebo score @ 24wk100 µg ODa,b
NCT01159912 · Phase 3
1 other source trial
0.93 vs 0.88 FF score @ 24wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
0.93 vs 0.88 FF score @ 24wk200/25 µg ODa,b
NCT01134042 · Phase 3 · combination · Asthma · phase 3
Evening PEF
absolute change · L/min
31.3 vs 9.6 placebo L/min200 µg ODc,d,a,b,e
NCT00603382 · Phase 2
show 3 more doses
25.7 vs 9.6 placebo L/min100 µg OD
NCT00603382 · Phase 2
30.3 vs 9.6 placebo L/min50 µg OD
NCT00603382 · Phase 2
23.6 vs 9.6 placebo L/min25 µg OD
NCT00603382 · Phase 2
26.4 vs -1.8 placebo L/min @ 12wk100/25 µg ODd,a,b,e
NCT01165138 · Phase 3
2 other source trials
39.7 vs 15.5 FF L/min @ 12wk100/25 µg OD
NCT01686633 · Phase 3
41.7 vs 15.5 FF L/min @ 12wk200/25 µg OD
NCT01686633 · Phase 3
Evening PEF
absolute change · L
24.9 vs 7.6 placebo L50 µg ODa,b,e
NCT01436110 · Phase 3 · registry result, not featured evidence
1 other source trial
22.8 vs 19.5 placebo L @ 12wk50 µg OD
NCT01436071 · Phase 3 · registry result, not featured evidence
39.2 vs -11.8 placebo L @ 12wk100/25 µg Once Dailya,b,e
NCT01498679 · Phase 3 · registry result, not featured evidence
1 other source trial
39.1 vs 10.5 Fluticasone Propionate L200/25 µg Once Daily
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
FEV1
absolute change · L
-0.227 vs -0.372 placebo L @ 4.14wk100/25 µg ODd,a,b,f
NCT01128569 · Phase 2 · registry result, not featured evidence
0.019 vs 0 FP/S L @ 24wk100/25 mcg Once Dailyc,d,a,b,f
NCT02301975 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.02 vs 0.014 FP/S L @ 24wk100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
FEV1 Trough
absolute value · L
2.83 vs 2.462 placebo L @ 12wk100/25 µg ODa,b
NCT01165138 · Phase 3
2.83 vs 2.462 placebo L @ 12wk100/25 µg ODa,b
NCT01165138 · Phase 3
FEV1 Wm0 24 h
absolute change · L
0.464 vs 0.328 FF L @ 24wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
0.464 vs 0.328 FF L @ 24wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
Morning PEF
absolute change · L/min
35.6 vs 13.6 placebo L/min200 µg ODc,d,g,b,e
NCT00603382 · Phase 2
show 3 more doses
29.5 vs 13.6 placebo L/min100 µg OD
NCT00603382 · Phase 2
33.5 vs 13.6 placebo L/min50 µg OD
NCT00603382 · Phase 2
27.2 vs 13.6 placebo L/min25 µg OD
NCT00603382 · Phase 2
14.9 vs 9.3 FF L/min @ 12wkc,d,g,b,e
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more dose
11.9 vs 8.9 FF L/min @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
Poorly-controlled Asthma Withdrawal
responder rate · % of participants
4.9% (n=123) vs 7.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
4.9% (n=123) vs 7.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
Rescue-free 24 h Periods
absolute change · percentage points
-0.9% (n=122) vs -2.1% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
-0.9% (n=122) vs -2.1% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
Rescue-free 24-h Period
percent change · % of baseline
32% (n=95) vs 21.9% (n=94) placebo200 µg ODc,d,a,b,e
NCT00603382 · Phase 2
show 3 more doses
40.8% (n=110) vs 21.9% (n=94) placebo100 µg OD
NCT00603382 · Phase 2
34.5% (n=98) vs 21.9% (n=94) placebo50 µg OD
NCT00603382 · Phase 2
29.3% (n=96) vs 21.9% (n=94) placebo25 µg OD
NCT00603382 · Phase 2
-3% (n=500) vs -4.2% (n=498) FP/S @ 24wk100/25 mcg Once Dailyd,a,b,e
NCT02301975 · Phase 3 · registry result, not featured evidence
Rescue-free 24-h Period
absolute change · percentage points
Rescue-free 24-hour periods
38.2% (n=197) vs 26.6% (n=193) FF @ 24wk200/25 µg OD
Rescue-free 24-hour periods
NCT01134042 · Phase 3 · combination · Asthma · phase 3
38.2% (n=197) vs 26.6% (n=193) FF @ 24wk200/25 µg OD
Rescue-free 24-hour periods
NCT01134042 · Phase 3 · combination · Asthma · phase 3
Severe Exacerbation Occurrence
event count · % of participants
15.3% (n=1009) vs 18.4% (n=1010) fluticasone furoate @ 76wk*100/25 µga,b
NCT01086384 · Phase 3 · registry result, not featured evidence · converted to % from 154 participants as posted
15.3% (n=1009) vs 18.4% (n=1010) fluticasone furoate @ 76wk*100/25 µga,b
NCT01086384 · Phase 3 · converted to % from 154 participants as posted
Severe Exacerbation Rate Annualized
event rate · Severe asthma exacerbations
200 vs 271 fluticasone furoate Severe asthma exacerbations @ 76wk100/25 µga,b
NCT01086384 · Phase 3 · registry result, not featured evidence
200 vs 271 fluticasone furoate Severe asthma exacerbations @ 76wk100/25 µga,b
NCT01086384 · Phase 3
Symptom-free 24 h Periods
absolute change · percentage points
-1% (n=122) vs -1.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
1 other source trial
25.1% (n=116) vs 16.8% (n=114) placebo50 µg OD
NCT01436110 · Phase 3 · registry result, not featured evidence
-1% (n=122) vs -1.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
Symptom-free 24-h Period
percent change · % of baseline
31.7% (n=95) vs 18.4% (n=94) placebo200 µg ODc,d,a,b,e
NCT00603382 · Phase 2
show 3 more doses
38.7% (n=110) vs 18.4% (n=94) placebo100 µg OD
NCT00603382 · Phase 2
31.1% (n=98) vs 18.4% (n=94) placebo50 µg OD
NCT00603382 · Phase 2
25.3% (n=96) vs 18.4% (n=94) placebo25 µg OD
NCT00603382 · Phase 2
32.5% (n=201) vs 14.6% (n=202) placebo @ 12wk100/25 µg ODd,a,b,e
NCT01165138 · Phase 3
3 other source trials
27.2% (n=345) vs 19.4% (n=346) FF @ 12wk100/25 µg OD
NCT01686633 · Phase 3
29% (n=346) vs 19.4% (n=346) FF @ 12wk200/25 µg OD
NCT01686633 · Phase 3
24.8% (n=153) vs 9% (n=154) placebo @ 12wk100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
Symptom-free 24-h Period
absolute change · percentage points
Symptom-free 24-hour periods
29.3% (n=197) vs 21% (n=193) FF @ 24wk200/25 µg OD
Symptom-free 24-hour periods
NCT01134042 · Phase 3 · combination · Asthma · phase 3
29.3% (n=197) vs 21% (n=193) FF @ 24wk200/25 µg OD
Symptom-free 24-hour periods
NCT01134042 · Phase 3 · combination · Asthma · phase 3
Well Controlled Asthma
responder rate · % of participants
89.5% (n=114) vs 78.2% (n=119) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
89.5% (n=114) vs 78.2% (n=119) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
Dropout rate
9.5%200 µg ODh
NCT00603382 · Phase 2
show 41 more results
10.9%100 µg OD
NCT00603382 · Phase 2
9%50 µg OD
NCT00603382 · Phase 2
14.4%25 µg OD
NCT00603382 · Phase 2
13.9%200 µg OD
NCT00603278 · Phase 2
16.2%100 µg OD
NCT00603278 · Phase 2
13.1%400 µg OD
NCT00603278 · Phase 2
10.7%300 µg OD
NCT00603278 · Phase 2
18.2%200 µg OD
NCT00603746 · Phase 2
16.7%800 µg OD
NCT00603746 · Phase 2
12.1%600 µg OD
NCT00603746 · Phase 2
7.9%400 µg OD
NCT00603746 · Phase 2
19.3%100 µg OD
NCT01159912 · Phase 3
10.9%100/25 µg OD
NCT01165138 · Phase 3
12.6%200 µg OD
NCT01431950 · Phase 3
16%100 µg OD
NCT01431950 · Phase 3
14.2%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
28%100 µg OD
NCT01563029 · Phase 2
27.5%50 µg OD
NCT01563029 · Phase 2
20.3%25 µg OD
NCT01563029 · Phase 2
13.9%50 mcg
NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy
—
NCT02502734 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
7.2%200/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
9.2%100/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
22.2%50 µg OD
NCT01436110 · Phase 3 · registry result, not featured evidence
11.3%50 µg OD
NCT01436071 · Phase 3 · registry result, not featured evidence
—100/25 µg
NCT01086384 · Phase 3 · registry result, not featured evidence
—200/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
—100/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
1.8%200/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
3.6%100/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
—100 µg AM
NCT01808339 · Phase 2 · registry result, not featured evidence
—100 µg PM
NCT01808339 · Phase 2 · registry result, not featured evidence
—100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
—100 µg
NCT01332292 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
—200 µg OD
NCT00766090 · Phase 2 · registry result, not featured evidence
—100 µg BID
NCT00766090 · Phase 2 · registry result, not featured evidence
—100/25 µgi
NCT01086384 · Phase 3
show 16 more results
—200/25 µg OD
NCT01018186 · Phase 3
—100/25 µg OD
NCT01018186 · Phase 3
—
NCT03248128 · Phase 3 · Asthma · phase 3
10.9%100/25 µg OD
NCT01165138 · Phase 3
7.2%200/25 µg OD
NCT01686633 · Phase 3
9.2%100/25 µg OD
NCT01686633 · Phase 3
14.2%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
—100/25 µg OD
NCT01147848 · Phase 3 · Asthma · phase 3
—100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
6.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
14.4%100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
12.3%200/25 µg Once Daily
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
—100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1.1%200 µg ODh
NCT00603382 · Phase 2
show 41 more results
1.8%100 µg OD
NCT00603382 · Phase 2
1%50 µg OD
NCT00603382 · Phase 2
1%25 µg OD
NCT00603382 · Phase 2
1%200 µg OD
NCT00603278 · Phase 2
2.9%100 µg OD
NCT00603278 · Phase 2
2%400 µg OD
NCT00603278 · Phase 2
0%300 µg OD
NCT00603278 · Phase 2
3%200 µg OD
NCT00603746 · Phase 2
0%800 µg OD
NCT00603746 · Phase 2
0.9%600 µg OD
NCT00603746 · Phase 2
0%400 µg OD
NCT00603746 · Phase 2
1.8%100 µg OD
NCT01159912 · Phase 3
1%100/25 µg OD
NCT01165138 · Phase 3
1.7%200 µg OD
NCT01431950 · Phase 3
1.7%100 µg OD
NCT01431950 · Phase 3
3.6%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
1.7%100 µg OD
NCT01563029 · Phase 2
0.8%50 µg OD
NCT01563029 · Phase 2
0%25 µg OD
NCT01563029 · Phase 2
—50 mcg
NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy
—
NCT02502734 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
0.9%200/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
0.9%100/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
0.9%50 µg OD
NCT01436110 · Phase 3 · registry result, not featured evidence
0%50 µg OD
NCT01436071 · Phase 3 · registry result, not featured evidence
—100/25 µg
NCT01086384 · Phase 3 · registry result, not featured evidence
—200/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
—100/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
0%200/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
0%100/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
—100 µg AM
NCT01808339 · Phase 2 · registry result, not featured evidence
—100 µg PM
NCT01808339 · Phase 2 · registry result, not featured evidence
—100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
—100 µg
NCT01332292 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
—200 µg OD
NCT00766090 · Phase 2 · registry result, not featured evidence
—100 µg BID
NCT00766090 · Phase 2 · registry result, not featured evidence
—100/25 µgi
NCT01086384 · Phase 3
show 16 more results
—200/25 µg OD
NCT01018186 · Phase 3
—100/25 µg OD
NCT01018186 · Phase 3
—
NCT03248128 · Phase 3 · Asthma · phase 3
1%100/25 µg OD
NCT01165138 · Phase 3
0.9%200/25 µg OD
NCT01686633 · Phase 3
0.9%100/25 µg OD
NCT01686633 · Phase 3
3.6%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
—100/25 µg OD
NCT01147848 · Phase 3 · Asthma · phase 3
—100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
1.6%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
2.6%100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
1.3%200/25 µg Once Daily
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
—100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
Serious AEs
0%200 µg ODh
NCT00603382 · Phase 2
show 41 more results
0.9%100 µg OD
NCT00603382 · Phase 2
0%50 µg OD
NCT00603382 · Phase 2
1%25 µg OD
NCT00603382 · Phase 2
0%200 µg OD
NCT00603278 · Phase 2
0%100 µg OD
NCT00603278 · Phase 2
1%400 µg OD
NCT00603278 · Phase 2
1%300 µg OD
NCT00603278 · Phase 2
2%200 µg OD
NCT00603746 · Phase 2
0%800 µg OD
NCT00603746 · Phase 2
0.9%600 µg OD
NCT00603746 · Phase 2
0%400 µg OD
NCT00603746 · Phase 2
3.5%100 µg OD
NCT01159912 · Phase 3
0%100/25 µg OD
NCT01165138 · Phase 3
3.4%200 µg OD
NCT01431950 · Phase 3
2.5%100 µg OD
NCT01431950 · Phase 3
3%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
0.8%100 µg OD
NCT01563029 · Phase 2
0.8%50 µg OD
NCT01563029 · Phase 2
0%25 µg OD
NCT01563029 · Phase 2
2.5%50 mcg
NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy
0%
NCT02502734 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0.8%100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0%100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
0.3%200/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
1.2%100/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
0%50 µg OD
NCT01436110 · Phase 3 · registry result, not featured evidence
0.8%50 µg OD
NCT01436071 · Phase 3 · registry result, not featured evidence
4.1%100/25 µg
NCT01086384 · Phase 3 · registry result, not featured evidence
0.5%200/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
1.5%100/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
0%200/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
0%100/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
0%100 µg AM
NCT01808339 · Phase 2 · registry result, not featured evidence
0%100 µg PM
NCT01808339 · Phase 2 · registry result, not featured evidence
0%100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
0%100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
0%100 µg
NCT01332292 · Phase 2 · registry result, not featured evidence
0%100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
0%200 µg OD
NCT00766090 · Phase 2 · registry result, not featured evidence
0%100 µg BID
NCT00766090 · Phase 2 · registry result, not featured evidence
4.1%100/25 µgi
NCT01086384 · Phase 3
show 16 more results
0.5%200/25 µg OD
NCT01018186 · Phase 3
1.5%100/25 µg OD
NCT01018186 · Phase 3
1.1%
NCT03248128 · Phase 3 · Asthma · phase 3
0%100/25 µg OD
NCT01165138 · Phase 3
0.3%200/25 µg OD
NCT01686633 · Phase 3
1.2%100/25 µg OD
NCT01686633 · Phase 3
3%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
1%100/25 µg OD
NCT01147848 · Phase 3 · Asthma · phase 3
1.4%100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
1.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0.8%100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0%100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
1.3%100/25 µg Once Daily
NCT01498679 · Phase 3 · registry result, not featured evidence
0.6%200/25 µg Once Daily
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
0%100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
200 µg ODh
headache 5.3% (placebo 10.6%)
nasopharyngitis 3.2% (placebo 1.1%)
oropharyngitis 3.2% (placebo 1.1%)
NCT00603382 · Phase 2
show 40 more results
100 µg OD
headache 10.9% (placebo 10.6%)
nasopharyngitis 3.6% (placebo 1.1%)
oropharyngitis 3.6% (placebo 1.1%)
NCT00603382 · Phase 2
50 µg OD
headache 6% (placebo 10.6%)
back pain 3% (placebo 0%)
oropharyngitis 1% (placebo 1.1%)
NCT00603382 · Phase 2
25 µg OD
headache 6.2% (placebo 10.6%)
back pain 0% (placebo 0%)
nasopharyngitis 0% (placebo 1.1%)
NCT00603382 · Phase 2
200 µg OD
headache 7.9% (placebo 5.6%)
nasopharyngitis 5% (placebo 7.5%)
upper respiratory tract infection 3% (placebo 2.8%)
NCT00603278 · Phase 2
100 µg OD
headache 8.6% (placebo 5.6%)
nasopharyngitis 8.6% (placebo 7.5%)
diarrhoea 3.8% (placebo 0%)
NCT00603278 · Phase 2
400 µg OD
headache 9.1% (placebo 5.6%)
cough 4% (placebo 0.9%)
nasopharyngitis 4% (placebo 7.5%)
NCT00603278 · Phase 2
300 µg OD
headache 7.8% (placebo 5.6%)
nasopharyngitis 6.8% (placebo 7.5%)
back pain 2.9% (placebo 0%)
NCT00603278 · Phase 2
200 µg OD
dysphonia 4% (placebo 1%)
oropharyngeal candidiasis 4% (placebo 1%)
headache 3% (placebo 9.7%)
NCT00603746 · Phase 2
800 µg OD
headache 9.8% (placebo 9.7%)
nasopharyngitis 6.9% (placebo 3.9%)
oral candidiasis 6.9% (placebo 0%)
NCT00603746 · Phase 2
600 µg OD
headache 11.2% (placebo 9.7%)
back pain 3.7% (placebo 1%)
pharyngolaryngeal pain 2.8% (placebo 1%)
NCT00603746 · Phase 2
400 µg OD
headache 9.9% (placebo 9.7%)
dysphonia 5% (placebo 1%)
nasopharyngitis 5% (placebo 3.9%)
NCT00603746 · Phase 2
100 µg OD
nasopharyngitis 7.9% (placebo 5.2%)
bronchitis 7% (placebo 6.1%)
headache 6.1% (placebo 4.3%)
NCT01159912 · Phase 3
100/25 µg OD
nasopharyngitis 10% (placebo 7.4%)
headache 5% (placebo 3.9%)
NCT01165138 · Phase 3
200 µg OD
headache 12.6%
nasopharyngitis 12.6%
bronchitis 6.7%
NCT01431950 · Phase 3
100 µg OD
bronchitis 11.8%
nasopharyngitis 11.8%
headache 10.1%
NCT01431950 · Phase 3
200/25 µg OD
nasopharyngitis 12.7%
headache 5.6%
bronchitis 3.6%
NCT01134042 · Phase 3 · combination · Asthma · phase 3
100 µg OD
cough 8.5% (placebo 5%)
headache 5.9% (placebo 1.7%)
rhinorrhoea 5.1% (placebo 1.7%)
NCT01563029 · Phase 2
50 µg OD
pharyngitis 5.8% (placebo 3.4%)
bronchitis 3.3% (placebo 0.8%)
nasopharyngitis 3.3% (placebo 3.4%)
NCT01563029 · Phase 2
25 µg OD
nasopharyngitis 7.6% (placebo 3.4%)
cough 5.9% (placebo 5%)
oropharyngeal pain 5.1% (placebo 0.8%)
NCT01563029 · Phase 2
50 mcg
upper respiratory tract infection 12.2% (placebo 13.8%)
nasopharyngitis 9.7% (placebo 10.5%)
rhinitis 6.7% (placebo 7.5%)
NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy
nasopharyngitis 6.9% (placebo 8.3%)
headache 5.2% (placebo 13.3%)
cough 3.4% (placebo 5%)
NCT02502734 · Phase 3 · registry result, not featured evidence
100 mcg once daily
nasopharyngitis 17.9%
NCT02094937 · Phase 3 · registry result, not featured evidence
100/25 mcg once daily
nasopharyngitis 15.6%
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
200/25 µg OD
headache 8.4%
nasopharyngitis 7.2%
upper respiratory tract infection 2%
NCT01686633 · Phase 3 · registry result, not featured evidence
100/25 µg OD
headache 8.4%
nasopharyngitis 6.4%
upper respiratory tract infection 2.3%
NCT01686633 · Phase 3 · registry result, not featured evidence
50 µg OD
headache 14.5% (placebo 11.3%)
nasopharyngitis 6.8% (placebo 5.2%)
pharyngitis 6% (placebo 8.7%)
NCT01436110 · Phase 3 · registry result, not featured evidence
50 µg OD
nasopharyngitis 5.8% (placebo 4.1%)
headache 5% (placebo 11.6%)
pharyngitis 5% (placebo 5%)
NCT01436071 · Phase 3 · registry result, not featured evidence
100/25 µg
headache 18.6%
nasopharyngitis 15.4%
upper respiratory tract infection 7.2%
NCT01086384 · Phase 3 · registry result, not featured evidence
200/25 µg OD
headache 17.3%
upper respiratory tract infection 14.9%
nasopharyngitis 9.4%
NCT01018186 · Phase 3 · registry result, not featured evidence
100/25 µg OD
headache 19.4%
upper respiratory tract infection 16.9%
nasopharyngitis 12.4%
NCT01018186 · Phase 3 · registry result, not featured evidence
200/25 µg PM
headache 16.1% (placebo 8.6%)
back pain 3.6% (placebo 0%)
sinus headache 3.6% (placebo 0%)
NCT01086410 · Phase 3 · registry result, not featured evidence
100/25 µg PM
headache 26.8% (placebo 8.6%)
arthralgia 3.6% (placebo 0%)
nasopharyngitis 3.6% (placebo 1.7%)
NCT01086410 · Phase 3 · registry result, not featured evidence
100 µg AM
headache 52.2% (placebo 36%)
upper respiratory tract infection 26.1% (placebo 8%)
nasopharyngitis 8.7% (placebo 4%)
NCT01808339 · Phase 2 · registry result, not featured evidence
100 µg PM
headache 41.7% (placebo 36%)
viral upper respiratory tract infection 20.8% (placebo 8%)
dysmenorrhoea 8.3% (placebo 8%)
NCT01808339 · Phase 2 · registry result, not featured evidence
100 µg/25 µg
bronchitis 4%
conjunctivitis 4%
headache 4%
NCT01453023 · Phase 2 · registry result, not featured evidence
100/25 µg OD
headache 55.6% (placebo 40.7%)
nasopharyngitis 11.1% (placebo 7.4%)
oropharyngeal pain 11.1% (placebo 7.4%)
NCT01128595 · Phase 2 · registry result, not featured evidence
100 µg
headache 11.5% (placebo 0%)
acute tonsillitis 3.8% (placebo 0%)
cough 3.8% (placebo 0%)
NCT01332292 · Phase 2 · registry result, not featured evidence
100/25 µg OD
headache 9.8% (placebo 17.6%)
dysphonia 3.9% (placebo 0%)
mouth ulceration 3.9% (placebo 0%)
NCT01128569 · Phase 2 · registry result, not featured evidence
200 µg OD
upper respiratory tract infection 5% (placebo 1.1%)
NCT00766090 · Phase 2 · registry result, not featured evidence
100 µg BID
upper respiratory tract infection 4.9% (placebo 1.1%)
NCT00766090 · Phase 2 · registry result, not featured evidence
100/25 µgi
headache 18.6%
nasopharyngitis 15.4%
upper respiratory tract infection 7.2%
NCT01086384 · Phase 3
show 15 more results
200/25 µg OD
headache 17.3%
upper respiratory tract infection 14.9%
nasopharyngitis 9.4%
NCT01018186 · Phase 3
100/25 µg OD
headache 19.4%
upper respiratory tract infection 16.9%
nasopharyngitis 12.4%
NCT01018186 · Phase 3
nasopharyngitis 10.4%
upper respiratory tract infection 7%
rhinitis allergic 4.2%
NCT03248128 · Phase 3 · Asthma · phase 3
100/25 µg OD
nasopharyngitis 10% (placebo 7.4%)
headache 5% (placebo 3.9%)
NCT01165138 · Phase 3
200/25 µg OD
headache 8.4%
nasopharyngitis 7.2%
upper respiratory tract infection 2%
NCT01686633 · Phase 3
100/25 µg OD
headache 8.4%
nasopharyngitis 6.4%
upper respiratory tract infection 2.3%
NCT01686633 · Phase 3
200/25 µg OD
nasopharyngitis 12.7%
headache 5.6%
bronchitis 3.6%
NCT01134042 · Phase 3 · combination · Asthma · phase 3
100/25 µg OD
nasopharyngitis 11.4%
headache 8.4%
upper respiratory tract infection 6.2%
NCT01147848 · Phase 3 · Asthma · phase 3
100/25 µg QD
upper respiratory tract infection 6.8%
NCT02730351 · Phase 4 · registry result, not featured evidence
100/25 mcg Once Daily
nasopharyngitis 12.1%
headache 8.1%
bronchitis 4%
NCT02301975 · Phase 3 · registry result, not featured evidence
100 mcg once daily
nasopharyngitis 17.9%
NCT02094937 · Phase 3 · registry result, not featured evidence
100/25 mcg once daily
nasopharyngitis 15.6%
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
100/25 µg Once Daily
upper respiratory tract infection 7.2% (placebo 9.1%)
headache 4.6% (placebo 1.9%)
nasopharyngitis 4.6% (placebo 8.4%)
NCT01498679 · Phase 3 · registry result, not featured evidence
200/25 µg Once Daily
upper respiratory tract infection 8.4%
nasopharyngitis 3.9%
rhinitis allergic 3.2%
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
100 µg/25 µg
bronchitis 4%
conjunctivitis 4%
headache 4%
NCT01453023 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dTrial phases differ: Phase 2 versus Phase 3.
  5. eThe assessment timepoint is not available for both results.
  6. fAssessment timepoints differ: 4.14 weeks versus 24 weeks.
  7. gPopulation context differs: age eligibility differs (adolescents and adults versus includes children).
  8. hPopulation comparability has not been reviewed for 41 of these studies.
  9. iPopulation comparability has not been reviewed for 13 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Fluticasone Furoate

FEV1 Evening Trough 0.367 vs 0.137 placebo L @ 8wk200 µg OD
absolute change · L
NCT00603382 · Phase 2
show 3 more results
0.341 vs 0.137 placebo L @ 8wk100 µg OD
NCT00603382 · Phase 2
0.266 vs 0.137 placebo L @ 8wk50 µg OD
NCT00603382 · Phase 2
0.239 vs 0.137 placebo L @ 8wk25 µg OD
NCT00603382 · Phase 2
Evening PEF 2.2 vs 0.4 placebo L @ 12wk100 µg OD
absolute change · L
PM PEF, Week 1 to 12
NCT01159912 · Phase 3
Evening PEF 1.5 vs -1.3 placebo L @ 24wk100 µg OD
absolute change · L
PM PEF, Week 1 to 24
NCT01159912 · Phase 3
Morning PEF 13.2 vs 5.7 placebo L @ 12wk100 µg OD
absolute change · L
AM PEF, Week 1 to 12
NCT01159912 · Phase 3
Morning PEF 13.9 vs 5 placebo L @ 24wk100 µg OD
absolute change · L
AM PEF, Week 1 to 24
NCT01159912 · Phase 3
FEV1 0.284 L @ 24wk200 µg OD
absolute change · L
No placebo or comparator arm
NCT01431950 · Phase 3
show 1 more result
0.208 L @ 24wk100 µg OD
NCT01431950 · Phase 3
Rescue-free 24-h Period 23.1% (n=109) @ 24wk200 µg OD
percent change · % of baseline
No placebo or comparator arm
NCT01431950 · Phase 3
show 1 more result
21.3% (n=108) @ 24wk100 µg OD
NCT01431950 · Phase 3
Evening PEF 7.2 L @ 24wk200 µg OD
absolute change · L
No placebo or comparator arm
NCT01431950 · Phase 3
show 1 more result
5.9 L @ 24wk100 µg OD
NCT01431950 · Phase 3
Morning PEF 13.2 L/min @ 24wk200 µg OD
absolute change · L/min
No placebo or comparator arm
NCT01431950 · Phase 3
show 1 more result
13.4 L/min @ 24wk100 µg OD
NCT01431950 · Phase 3
Symptom-free 24-h Period 19.6% (n=109) @ 24wk200 µg OD
percent change · % of baseline
No placebo or comparator arm
NCT01431950 · Phase 3
show 1 more result
17.5% (n=108) @ 24wk100 µg OD
NCT01431950 · Phase 3
Height Velocity cm Per 5.905 vs 6.065 placebo per year @ 52wk50 mcg
absolute value · per year
NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy
show 1 more result
6.281 vs 6.222 placebo per year @ 12wk50 mcg
NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy
Height Velocity Lt3rd Percentile 7% (n=231) vs 9% (n=226) placebo @ 52wk50 mcg
responder rate · % of participants
NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy

+ 11 further endpoints in the CSV export.

fluticasone furoate/vilanterol

FEV1 Weighted Mean 0-4h 2.082 vs 1.994 FF L @ 12wk
absolute value · L
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
1.762 vs 1.711 FF L @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
Rescue-free 24-h Period 25.9% (n=453) vs 25.8% (n=447) FF @ 12wk
absolute change · percentage points
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
27.3% (n=336) vs 25.6% (n=335) FF @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
Symptom-free 24-h Period 25.7% (n=453) vs 24.6% (n=447) FF @ 12wk
absolute change · percentage points
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
27.2% (n=336) vs 25.8% (n=335) FF @ 12wk
NCT03248128 · Phase 3 · Asthma · phase 3
ACQ-5 -1.21 vs -1.09 FF score @ 24wk
absolute change · score
NCT03248128 · Phase 3 · Asthma · phase 3
show 1 more result
-1.25 vs -1.13 FF score @ 24wk
NCT03248128 · Phase 3 · Asthma · phase 3
FEV1 AUC0-24 0.341 vs 0.377 Fluticasone Propionate/Salmeterol L @ 24wk100/25 µg OD
absolute change · L
NCT01147848 · Phase 3 · Asthma · phase 3
FEV1 AUC0-4 0.316 vs 0.346 Fluticasone Propionate/Salmeterol L @ 0wk100/25 µg OD
absolute change · L
NCT01147848 · Phase 3 · Asthma · phase 3
show 1 more result
0.36 vs 0.394 Fluticasone Propionate/Salmeterol L @ 24wk100/25 µg OD
NCT01147848 · Phase 3 · Asthma · phase 3
Max Post-exercise FEV1 Fall 15.02% (n=70) vs 16.71% (n=69) FP @ 2wk100/25 µg QD
percent change · % of baseline
NCT02730351 · Phase 4 · registry result, not featured evidence
show 1 more result
11.9% (n=68) vs 14.05% (n=69) FP @ 2wk100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
AM PEF Change L/Min 8.9 vs 3.7 FP/S L/min @ 24wk100/25 mcg Once Daily
absolute change · L/min
NCT02301975 · Phase 3 · registry result, not featured evidence
Evening PEF Change L/Min 5.5 vs 0.5 FP/S L/min @ 24wk100/25 mcg Once Daily
absolute change · L/min
NCT02301975 · Phase 3 · registry result, not featured evidence
Rescue-free 24-hr Periods 32.4% (n=155) vs 31.5% (n=152) Fluticasone Propionate200/25 µg Once Daily
absolute change · percentage points
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3
Symptom-free 24-hr Periods 25.4% (n=155) vs 20.6% (n=152) Fluticasone Propionate200/25 µg Once Daily
absolute change · percentage points
NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fluticasone Furoate's landscape · fluticasone furoate/vilanterol's landscape